Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

45 Press Releases
DateTitleCompany
09 Dec 14 Phase III guanfacine hydrochloride extended release (GXR) study shows improvement in core symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents Shire plc,
Published by
Shire
06 Nov 14 Shire to Participate at the Credit Suisse 2014 Global Healthcare Conference Shire plc,
Published by
PR Newswire
15 Oct 14 European ADHD Awareness Week 2014: New Report Gives Voice to People Living with ADHD and Calls for Europe-Wide Changes in Policies and Attitudes Shire plc,
Published by
Corporate Communications, Shire
15 Oct 14 Shire Announces 2014 Excellence in ADHD Patient Group Award Winners Shire plc
25 Jun 14 Shire Comments on AbbVie's Unchanged Proposal Shire plc,
Published by
PR Newswire
23 Jun 14 Shire Launches Excellence in ADHD Patient Group Awards Shire plc
23 Jun 14 Shire to Host Investor Call Shire plc,
Published by
PR Newswire
18 Dec 12 Positive response from European regulatory procedure supports approval of Elvanse® (lisdexamfetamine dimesylate) for ADHD Shire plc
06 Sep 12 Shire Settles All Pending Litigation With Anchen and TWi Concerning INTUNIV® Shire plc,
Published by
PR Newswire
13 Apr 12 Shire adds new technology platform and phase 2 product candidate to its Regenerative Medicine business Shire plc
12 Apr 12 Shire plc: First Quarter 2012 Results Date Notification - April 26, 2012 Shire plc,
Published by
PR Newswire
01 Mar 12 Shire Receives Prestigious EURORDIS Company Award for Exemplary Work in Rare Diseases SHIRE PLC
24 Jun 11 European Authorities Approve New Manufacturing Facility for Shire's REPLAGAL® (agalsidase alfa) Shire plc,
Published by
PR Newswire
18 Mar 11 European Commission Approves Self-Administration Label for FIRAZYR® (icatibant) for the Symptomatic Treatment of Acute Hereditary Angioedema Attacks Shire plc,
Published by
PharmiWeb.com
03 Mar 11 European Commission Approves Self-Administration Label for FIRAZYR(R) (icatibant) for the Symptomatic Treatment of Acute Hereditary Angioedema Attack Shire plc,
Published by
PharmiWeb.com
01 Dec 10 Shire Reports Positive Efficacy and Safety Results From FAST-3 Study of FIRAZYR® (icatibant) for Acute Attacks of Hereditary Angioedema Shire plc,
Published by
PharmiWeb.com
18 Oct 10 Third Quarter 2010 Results Date Notification - October 29, 2010 Shire plc,
Published by
PR Newswire
14 Sep 10 Shire Update on ProAmatine® (midodrine HCl) Shire plc,
Published by
PharmiWeb.com
26 Aug 10 Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease Shire plc,
Published by
PR Newswire
17 Aug 10 Shire plc - Statement re ProAmatine Shire plc,
Published by
PR Newswire
03 Jun 10 INTUNIV(TM) - Shire Files Suit Against Anchen Pharmaceuticals, Inc. and Anchen, Inc. Shire plc,
Published by
PR Newswire
29 May 10 Shire Receives LIALDA(R) Paragraph IV Notice Letter From Zydus Pharmaceuticals Shire plc,
Published by
PR Newswire
19 May 10 Shire Receives 2010 Corporate Award From the National Organization for Rare Disorders (NORD) for the Development of VPRIV (velaglucerase alfa for Injection) Shire plc,
Published by
PR Newswire
13 May 10 INTUNIV(TM) - Shire Files Suit Against Actavis Elizabeth LLC and Actavis Inc. Shire plc,
Published by
PR Newswire
29 Apr 10 Shire's Replenished Portfolio Drives Excellent Quarterly Performance Shire plc,
Published by
PR Newswire
27 Apr 10 Shire Receives INTUNIV(TM) Paragraph IV Notice Letter From Anchen Shire plc,
Published by
PR Newswire
23 Apr 10 INTUNIV(TM) - Shire Files Suit Against Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries, Ltd. Shire plc,
Published by
PR Newswire
16 Mar 10 Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals Shire plc,
Published by
PR Newswire
15 Mar 10 New Board Director Appointed Shire plc,
Published by
PR Newswire
04 Mar 10 District Court Upholds FDA's Grant of 5-Year Market Exclusivity to VYVANSE(R) Shire plc,
Published by
PR Newswire
Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.